{"filings":[{"id":2380676,"accession_number":"0001437749-26-028628","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2026-08-20T19:27:04+00:00","items":["8.01","9.01","2.02"],"status":"ready","headline":"Integrated BioPharma's MDC subsidiary names Michael Richtmyer Head of Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael G. Richtmyer appointed Head of Operations at Manhattan Drug Company, effective August 3, 2026.","Richtmyer brings 35+ years in pharma/nutraceutical ops; was President of Tishcon Corp., overseeing 2 contract manufacturing sites.","He previously worked at Integrated BioPharma from 1991 to 1999 and returns with expanded leadership experience.","Will lead manufacturing, supply chain, quality systems, and scalable growth across MDC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1401836,"accession_number":"0001437749-26-022415","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2026-07-02T14:37:20+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Integrated BioPharma extends revolving credit line to April 2027, enters $250K equipment note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolving line of credit extended to April 14, 2027; maximum principal remains $4,000,000.","New $250,000 Convertible Line of Credit Note (Daily SOFR) for equipment/vehicles replaces matured $500,000 note.","Interest on new note: Daily SOFR + 250 bps before conversion; after conversion, Daily SOFR or fixed rate at Bank's option.","Amendment fee of $4,000 and legal fees of $2,500 paid to PNC Bank as conditions to effectiveness.","Borrower reaffirms all security agreements, liens, and representations; no event of default exists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90615,"accession_number":"0001437749-26-015928","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma reports Q3 net loss of $0.8M, revenue falls 27.3% to $10.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $0.8M ($0.03 loss per share) vs net income $0.6M ($0.02 EPS) in Q3 2025.","Revenue $10.1M, down 27.3% from $13.9M; operating loss $1.1M vs $0.7M income.","Nine-month net loss $1.5M ($0.05 loss per share) vs net income $1.0M ($0.03 EPS).","Two largest customers in Contract Manufacturing segment represented 90% of nine-month revenue (83% prior year)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":34076000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90614,"accession_number":"0001437749-26-012368","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["9.01","8.01"],"status":"ready","headline":"Integrated BioPharma receives 3-month extension of PNC line of credit to July 14, 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["PNC Bank notified Integrated BioPharma and subsidiary Manhattan Drug on April 14, 2026.","Line of credit expiration extended from April 15, 2026 to July 14, 2026.","Extension subject to PNC's sole discretion to designate a later date via written notice.","No changes to other terms of the promissory note dated April 15, 2025 were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100290,"accession_number":"0001437749-26-004553","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Integrated Biopharma subsidiary amends lease with related party; rent increases to $1.1M/yr through 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Manhattan Drug subsidiary reduced leased space from 116,175 to 110,095 sq ft at Hillside, NJ facility.","Annual base rent increased from $845,966 to $1,100,950 (3% annual escalator); lease extended to Jan 31, 2029.","Lessor Vitamin Realty is 100% owned by estate of former chairman and by co-CEOs who are also directors (related party).","Tenant also pays proportionate share of operating expenses (70.12% of building).","All other terms of original lease remain in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100289,"accession_number":"0001437749-26-003808","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q2 revenue down 10.3%, swings to net loss of $0.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.3M vs $12.6M Q2 prior year; operating loss $0.9M vs income $0.2M.","Net loss $0.8M vs net income $0.1M; diluted EPS $(0.03) vs $0.00.","Six-month revenue $24.0M vs $26.2M; operating loss $0.7M vs income $0.7M.","Two largest contract manufacturing customers accounted for ~89% of total revenue.","Selling and administrative expenses decreased slightly to $0.9M from $1.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":23969000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116621,"accession_number":"0001437749-25-036573","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders re-elect director, approve 3-year say-on-pay frequency, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eric Friedman re-elected as Class III director with 20.66M votes for, 183k withheld, and 1.81M broker non-votes.","Non-binding advisory vote: 20.40M shares favor 3-year frequency for executive compensation votes.","Executive compensation say-on-pay approved: 20.79M for, 56,978 against, 700 abstain.","Ratification of CBIZ CPAs P.C. as independent auditors for FY2026: 22.54M for, 113k against, 1,138 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116620,"accession_number":"0001437749-25-034091","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q1 revenue down 6.6% to $12.7M; net income $0.1M, EPS $0.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.7M, down 6.6% from $13.6M YoY; gross profit $1.0M vs $1.4M.","Net income $123K ($0.00 basic EPS) vs $259K ($0.01) in prior year quarter.","Operating income $163K vs $490K YoY, driven by lower gross profit.","Two largest customers in Contract Manufacturing = 87% of total revenue (85% in prior year)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":12689000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133073,"accession_number":"0001437749-25-029717","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q4 rev $14.2M (+11.8%); net loss $0.2M on tax; FY net income $808k","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $14.2M vs $12.7M (+11.8%); operating income $589k vs $402k.","Q4 net loss $178k ($0.01 loss per share) vs net income $268k ($0.01 EPS) prior year; tax expense $773k.","FY2025 revenue $54.4M (+8.0%); net income $808k ($0.03 diluted EPS) vs $112k ($0.00 EPS) prior year.","FY operating income $2.0M vs $251k; selling and administrative expenses flat.","Weighted average diluted shares for FY 31.2M vs 30.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149656,"accession_number":"0001437749-25-016809","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q2 fiscal 2025 revenue up 6.1% to $13.9M, net income $0.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $13.9M vs $13.1M YoY; nine-month revenue $40.2M (+6.9%).","Operating income $0.7M vs $0.4M; nine-month operating income $1.4M vs loss $0.2M.","Net income $0.02 EPS vs $0.01; nine-month net income $1.0M ($0.03 EPS) vs loss $0.2M.","Two largest customers in contract manufacturing represented 83% of total revenue in nine-month period.","Co-CEOs cite customer base expansion and revenue growth from core business."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":40178000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149655,"accession_number":"0001437749-25-012917","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Integrated BioPharma replaces auditor Marcum with CBIZ CPAs after Marcum's attest business acquisition","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marcum LLP resigned as auditor effective April 24, 2025; CBIZ CPAs P.C. engaged for fiscal year ending June 30, 2025.","Marcum's reports for FY 2024 and 2023 were unqualified, with no adverse opinions or modifications.","No disagreements or reportable events between the Company and Marcum during the past two fiscal years and interim period.","No prior consultations with CBIZ CPAs regarding accounting principles, audit opinions, or reportable events.","Change approved by Audit Committee; Marcum provided a letter to the SEC agreeing with the disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149654,"accession_number":"0001437749-25-012475","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["1.02","1.01","2.03","9.01"],"status":"ready","headline":"Integrated BioPharma enters $4.5M PNC credit facility; replaces prior debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $4M revolving line of credit and $500K convertible equipment line from PNC Bank (SOFR+250bps).","Maturity date April 5, 2026; borrowed funds for working capital and equipment purchases.","Prior credit facility fully repaid and terminated; payoff amount was $7,864.51 on April 15, 2025.","Reimbursement agreement covers standby/commercial letters of credit up to $1M sublimit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168703,"accession_number":"0001437749-25-003765","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q2 rev $12.6M (+9.6% YoY); net income $0.1M vs loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.6M for Q2 ended Dec 31, 2024, up from $11.5M a year ago; six-month rev $26.2M (+7.4%).","Operating income $0.2M vs operating loss $0.5M in prior year quarter; six-month op income $0.7M.","Net income $0.1M ($0.00 EPS) vs net loss $0.4M ($(0.01) EPS) in prior year quarter.","Two largest contract manufacturing customers represented ~82% of total revenue in the six-month period.","Co-CEOs cite customer base expansion and core business focus as drivers of revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":26231000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185813,"accession_number":"0001437749-24-036441","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Integrated BioPharma elects two Class I directors, ratifies Marcum as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Damon DeSantis as Class I director: 20,448,871 for, 142,036 withheld, 1,342,353 broker non-votes.","Elected Riva Sheppard as Class I director: 20,301,671 for, 289,236 withheld, 1,342,353 broker non-votes.","Ratified appointment of Marcum LLP as independent auditor for FY2025: 21,905,273 for, 9,287 against, 18,700 abstain.","Total shares voted: 21,933,260 of 30,099,610 entitled; quorum present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185812,"accession_number":"0001437749-24-035331","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q1 revenue $13.6M (+5.4% YoY); net income $0.3M vs loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $13.6M versus $12.9M YoY; operating income $0.5M versus operating loss of $54K.","Net income $259K ($0.01 diluted EPS) compared to net loss of $59K ($0.00) in prior year.","Two largest customers represented 85% of revenue (down from 91%), reflecting diversification.","No forward guidance or dividend changes were provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":13617000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202382,"accession_number":"0001437749-24-029810","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q4 net income $0.3M ($0.01/share); FY net income $112K vs loss $34K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue Q4 $12.7M (-2.3% YoY); FY $50.3M (-0.7% YoY).","Operating income improved to $402K Q4 and $251K FY, from $79K and $120K prior.","Net income Q4 $268K ($0.01 diluted) vs $40K ($0.00); FY net income $112K ($0.00) vs net loss $34K.","Two largest customers accounted for 90% of FY2024 revenue (89% prior year).","Co-CEOs cite focus on core businesses and new prospects to diversify customer base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218501,"accession_number":"0001437749-24-016041","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q3 net income $0.3M vs $16k YoY; revenue flat at $13.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Quarterly revenue $13.1M (flat YoY); operating income $0.4M vs $44k prior year.","Net income $0.3M ($0.01 diluted EPS) vs $16k ($0.00) in Q3 2023.","Nine-month revenue $37.6M (down 0.3% YoY); net loss $0.2M ($0.01 loss per share).","Two largest contract manufacturing customers represent ~90% of total revenue; management plans to expand customer base by FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":37571000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238404,"accession_number":"0001437749-24-003763","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q2 revenue down 6.5% to $11.5M; net loss widens to $0.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $11.5M vs $12.3M in prior-year quarter (-6.5%).","Operating loss of ~$0.5M vs ~$33K loss a year ago.","Net loss of $0.4M ($0.01 per share) vs $3K loss ($0.00) prior year.","Six-month revenue $24.4M vs $24.6M; net loss $0.4M vs $0.1M.","Two largest customers represent ~90% of total revenue; company aims to diversify by FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":24424000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255898,"accession_number":"0001437749-23-033049","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Integrated BioPharma holds 2023 annual meeting; elects Class II directors, approves advisory pay vote, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Christina Kay, Robert Canarick, and William H. Milmoe elected as Class II directors to serve until 2026.","Non-binding advisory vote on executive compensation approved: 19,964,583 for, 2,510,524 against, 1,715 abstain.","Ratification of Marcum LLP as independent auditor for FY ending June 30, 2024 passed: 23,762,534 for, 7,281 against.","Vote results: Kay 20,393,822 for; Canarick 22,301,725 for; Milmoe 22,285,400 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255897,"accession_number":"0001437749-23-031188","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q1 revenue up 4.9% to $12.9M; net loss widens to $59K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.9M vs $12.3M YoY, a 4.9% increase.","Operating loss of $54K vs operating income of $30K in prior year.","Net loss of $59K ($0.00 per share) vs net loss of $35K ($0.00 per share).","Two largest customers represent 91% of Q1 revenue in Contract Manufacturing Segment.","Co-CEOs cite revenue growth from top customers."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":12915000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":273318,"accession_number":"0001437749-23-026058","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2023-09-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma FY2023 revenue down 9.8%; net loss of $34K vs prior year net income $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $13.0M (-2.3% YoY); operating income $79K vs $438K; net income $40K ($0.00 EPS).","FY2023 revenue $50.7M (-9.8%); operating income $120K vs $2.7M; net loss $34K ($0.00 EPS).","Diluted EPS $0.00 for both Q4 and FY; prior year $0.05 and $0.12 respectively.","Contract Manufacturing Segment contributed 95% of total revenue; two largest customers accounted for ~89%.","Warehousing/distribution business segment grew slightly as a percentage of total revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":290249,"accession_number":"0001437749-23-013899","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q3 revenue down 16% YoY; net income falls to $16K from $0.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Quarterly revenue $13.1M, down 16.2% from $15.6M in prior year.","Operating income $44K vs $1.0M; net income $16K ($0.00 EPS) vs $0.8M ($0.03 EPS).","Nine-month net loss $74K vs net income $2.3M in prior year.","Two largest customers fell from 91% to 88% of revenue; overstocking during pandemic cited as cause."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":37678000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311163,"accession_number":"0001437749-23-007377","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Integrated BioPharma founder, Executive Chairman & President Edward G. Kay dies at 86","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edward G. Kay, founder, Executive Chairman and President, passed away on March 20, 2023, at age 86.","Board will convene later to appoint a new chairperson; positions remain vacant for now.","Kay held president, director, and chairman roles; no successor named at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311162,"accession_number":"0001437749-23-007022","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2023-03-17T23:59:59+00:00","items":[],"status":"ready","headline":"Integrated BioPharma amends credit agreement to replace LIBOR with Term SOFR plus 0.10%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fourth Amendment to Revolving Credit, Term Loan and Security Agreement dated March 16, 2023.","Interest rate benchmark changed from LIBOR to Term SOFR Rate plus a 10 basis point SOFR Adjustment.","Outstanding LIBOR-based loans may remain until their term; new requests use Term SOFR.","As of March 16, 2023, no outstanding borrowings or pending requests under the agreement.","Amendment involves Integrated BioPharma and its subsidiaries with PNC Bank as agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":311161,"accession_number":"0001437749-23-003052","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2023-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q2 revenue falls 15.6% YoY; swings to net loss of $55K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.3M vs $14.6M a year ago; operating loss ~$33K vs income $0.7M.","Net loss of $55K ($0.00 per share) vs net income $1.0M ($0.04) in prior-year quarter.","Six-month revenue $24.6M (-9.9% YoY); net loss $90K vs income $1.5M.","Co-CEOs cite customer overstocking during pandemic as primary cause of sales decline.","Two largest customers in Contract Manufacturing Segment represent ~91% of total revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":24580000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329776,"accession_number":"0001437749-22-028569","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":[],"status":"ready","headline":"Integrated Biopharma subsidiary leases 12,500 sq ft warehouse for 5 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease effective Dec 1, 2022 with Elizabeth Industrial Park, LLC through Nov 30, 2027.","First-year rent $118,800, escalating to $134,400 in year five.","Additional rent of at least $1,300/month for pro-rata share of operating expenses.","Integrated Biopharma provides irrevocable guarantee of all lease obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329775,"accession_number":"0001437749-22-028094","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2022-11-28T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Integrated BioPharma stockholders re-elect Eric Friedman as Class III director, ratify Marcum LLP as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eric Friedman elected as Class III director for term until 2025 Annual Meeting; vote: 21.7M for, 85.9K withheld, 1.6M broker non-votes.","Ratification of Marcum LLP as independent auditor for FY ending June 30, 2023 approved: 23.4M for, 25.8K against, 30K abstain.","Quorum of 23.5M shares out of 29.9M outstanding shares present at November 28, 2022 Annual Meeting.","No other matters were voted upon at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329774,"accession_number":"0001437749-22-027168","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q1 net loss of $35K vs net income $516K YoY; revenue down 3% to $12.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.3M, down ~3.1% from $12.8M in Q1 FY2022.","Operating income fell to $30K from $585K in the year-ago quarter.","Net loss of $35K ($0.00 EPS) vs net income of $516K ($0.02) in Q1 FY2022.","Two largest Contract Manufacturing customers were 85% of revenue (down from 91%).","Co-CEOs cite pandemic overstocking by customers as key headwind."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":12326000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329772,"accession_number":"0001437749-22-027367","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K/A","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma reports Q1 FY2023 net loss; revenue down 3.1% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.3M, down ~3.1% YoY from $12.8M.","Operating income $30K vs $585K; net loss $35K vs net income $516K.","Diluted EPS $0.00 per share vs $0.02 in prior-year quarter.","Co-CEOs cite customer overstocking from pandemic as reason for sales decline.","Two largest customers in Contract Manufacturing segment made up 85% of revenue (91% a year ago)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":12326000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":329773,"accession_number":"0001437749-22-024634","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2022-10-24T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Integrated BioPharma dismisses Friedman LLP and appoints Marcum LLP as auditor after merger","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Friedman LLP combined with Marcum LLP effective September 1, 2022, then operated separately for Integrated BioPharma.","On October 21, 2022, the Audit Committee ratified the dismissal of Friedman and engagement of Marcum.","No disagreements or reportable events occurred in the two most recent fiscal years or subsequent interim period.","Friedman's audit reports for FY2022 and FY2021 were unqualified and not modified as to uncertainty or scope."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347349,"accession_number":"0001437749-22-022390","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2022-09-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q4 FY22 net income $1.5M, down 67% YoY; revenue falls 22%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $13.3M, down 22.2% from $17.1M; operating income $0.4M vs $1.3M.","Full fiscal year revenue $56.2M, down 11.6% from $63.6M; operating income $2.7M vs $5.8M.","Full year diluted EPS $0.12 vs $0.25; net income $3.8M vs $8.0M.","Co-CEOs cite normalization after pandemic-driven safety stock and demand as reasons for decline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":347348,"accession_number":"0001437749-22-017194","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2022-07-15T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Integrated Biopharma expands leased space via related-party deal, cancels smaller lease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MDC (wholly owned subsidiary) leased additional 40,524 sq ft, increasing total to 116,685 sq ft from Vitamin Realty.","Annual base rent rises from $533,124 to $845,966; termination date remains January 31, 2026.","Concurrent cancellation of AgroLabs lease for 2,700 sq ft effective July 1, 2022, saving $32,239 in annual payments.","Vitamin Realty is 100% owned by the Company's Executive Chairman and Co-CEOs (related-party transaction).","No outstanding amounts owed by AgroLabs at cancellation; all other lease terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363782,"accession_number":"0001437749-22-015503","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["9.01","5.07"],"status":"ready","headline":"Integrated BioPharma appoints Damon DeSantis to Board, replacing Carl DeSantis","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carl DeSantis resigned as Class I Director on June 20, 2022; no disagreement cited.","Damon DeSantis appointed to fill vacancy, will serve as Class I Director until 2024.","Damon is son of Carl DeSantis, a principal shareholder, and serves on boards of MacPherson's and Celsius Holdings (CELH).","Damon received a stock option for 50,000 shares at closing price on June 27, 2022, vesting quarterly through June 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":363781,"accession_number":"0001437749-22-012086","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","5.05","9.01"],"status":"ready","headline":"Integrated BioPharma Q3 net income falls 36% to $0.8M; revenue $15.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $15.6M, down 8.4% YoY from $17.1M; operating income $1.0M vs $1.7M.","Net income $0.8M ($0.03 diluted EPS) vs $1.2M ($0.04) in prior-year quarter.","Nine-month revenue $43.0M, down 7.6%; net income $2.3M vs $3.5M.","Revenue decline attributed to normalization of customer safety stock from COVID-19 pandemic.","Two largest contract manufacturing customers still represent ~91% of total revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":42979000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":383542,"accession_number":"0001437749-22-003026","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2022-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma (INBP) Q1 net income $1.0M vs $1.2M; revenue up 2.1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for quarter ended Dec 31, 2021: $14.6M, up 2.1% YoY from $14.3M.","Operating income fell to $0.7M from $1.2M; net income $1.0M vs $1.2M.","EPS basic unchanged at $0.04; diluted $0.03 vs $0.04.","Six-month revenue down 7.1% to $27.3M; net income $1.5M vs $2.3M.","Co-CEOs attribute 6-month decline to prior year's COVID-related safety stock and demand."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":27345000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401364,"accession_number":"0001437749-21-027467","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2021-11-29T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"2021 annual meeting results: directors elected, executive compensation approved, auditor ratified","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["E Gerald Kay, Riva Sheppard, and Carl DeSantis elected as Class I directors until 2024 annual meeting.","Non-binding advisory vote on executive compensation approved with 20.2M for, 0.7M against, 2.1M abstain.","Ratification of Friedman LLP as independent auditor for FY ending June 30, 2022 approved (23.8M for, 6.4K against).","Total shares voted: 24.1M out of 29.8M eligible (quorum present)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":401363,"accession_number":"0001437749-21-026193","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma Q1 revenue down 16% to $12.8M; net income falls to $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $12.8M vs $15.2M YoY, a decrease of 16.0%.","Operating income $0.6M vs $1.5M; net income $0.5M ($0.02 basic EPS) vs $1.0M ($0.04 basic EPS).","Diluted EPS $0.02 vs $0.03 in the prior-year quarter.","Two largest customers in Contract Manufacturing Segment accounted for ~91% of revenue, consistent with YoY.","Co-CEOs cite pandemic-related safety stock and consumer demand in prior year as cause for revenue decline."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":12751000.0,"consensus_period":"2021-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420317,"accession_number":"0001437749-21-021383","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2021-09-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Integrated BioPharma reports FY net income $8.0M, revenue up 20.5% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for FY ended June 30, 2021: $63.6M, up 20.5% YoY from $52.8M.","FY net income $8.0M ($0.27 basic EPS) vs $4.1M ($0.14 basic EPS) prior year.","Q4 revenue $17.1M (+26.7% YoY); Q4 net income $4.5M ($0.15 basic EPS) vs $1.9M ($0.06).","FY operating income $5.8M vs $3.3M prior year; PPP forgiveness of $1.7M boosted other income.","Two customers represent ~92% of total revenue in both FY2021 and FY2020, per co-CEOs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":420316,"accession_number":"0001437749-21-016530","cik":1016504,"company_name":"INTEGRATED BIOPHARMA INC","ticker":"INBP","form_type":"8-K","filed_at":"2021-07-07T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Integrated Biopharma's $1.64M PPP loan forgiven by SBA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SBA paid $1,658,652.85 to PNC; $1,639,300 applied to principal, $19,352.85 to accrued interest.","PPP loan originally disclosed in March 2020 10-Q; now fully satisfied with no repayment obligation.","Company received notification on June 30, 2021; agreement terminated via SBA forgiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5664961.882365863,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}